The earnings call reflects strong overall performance with significant revenue growth, successful product approvals, and strategic pipeline advancements. However, challenges in the China market, anticipated headwinds from VBP and IRA, and increased operating expenses highlight areas of concern. The sentiment is balanced between strong growth prospects and operational challenges.

Company Guidance

During the call, AstraZeneca provided detailed guidance on its performance and future outlook. In 2024, the company achieved a total revenue increase of 21% and a core EPS growth of 19%. Core operating expenses rose by 14%, indicating efficient leverage relative to revenue growth. The company initiated nine high-value pivotal trials, projected to generate over $5 billion in peak revenue. AstraZeneca aims to launch 20 new medicines by 2030, with eight already approved. For 2025, the company anticipates a high single-digit percentage increase in total revenue and a low double-digit percentage increase in core EPS. The company also expects a 70 basis points decline in product sales growth margin due to factors such as IRA in the U.S. and VBP inclusion in China. AstraZeneca plans to increase CapEx by approximately 50% in 2025 to support manufacturing and technology investments. Despite challenges, such as ongoing investigations in China and potential import duty fines, AstraZeneca remains focused on sustaining growth through its diverse product portfolio and strategic investments.

Strong Revenue Growth

Total revenue increased by 21% in 2024, with a core EPS growth of 19%. This exceeded the twice updated guidance range of a high teens percentage increase.

Successful Product Launches and Approvals

Eight new medicines have been approved to date, including Datroway, with significant contributions from oncology products like Tagrisso, Enhertu, and Imfinzi.

Emerging Markets Growth

Emerging market growth was strong at 22% in 2024, with substantial opportunities noted in China and other emerging markets.

Pipeline Advancements

Nine high-value pivotal trials readouts in 2024, representing over $5 billion in non-risk adjusted peak year revenue, with more anticipated in 2025.

Dividend Increase

AstraZeneca increased its full-year 2024 dividend to $3.10 per share and plans to increase the 2025 dividend to $3.20.

---

AstraZeneca (AZN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AZN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 29, 2025	2025 (Q1)	1.11 / -	1.03	―	―	―
Feb 06, 2025	2024 (Q4)	1.03 / 1.04	0.725	44.14% (+0.32)
Nov 12, 2024	2024 (Q3)	1.02 / 1.04	0.865	20.23% (+0.18)
Jul 25, 2024	2024 (Q2)	0.98 / 0.99	1.075	-7.91% (-0.08)
Apr 25, 2024	2024 (Q1)	0.96 / 1.03	0.96	7.29% (+0.07)
Feb 08, 2024	2023 (Q4)	0.73 / 0.72	0.69	5.07% (+0.04)
Nov 09, 2023	2023 (Q3)	0.84 / 0.86	0.835	3.59% (+0.03)
Jul 28, 2023	2023 (Q2)	0.99 / 1.07	0.86	25.00% (+0.21)
Apr 27, 2023	2023 (Q1)	0.85 / 0.96	0.945	1.59% (+0.02)
Feb 09, 2023	2022 (Q4)	0.67 / 0.69	0.835	-17.37% (-0.15)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

AZN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 06, 2025	$70.94	$72.36	+2.00%
Nov 12, 2024	$64.79	$65.19	+0.62%
Jul 25, 2024	$79.23	$78.05	-1.49%
Apr 25, 2024	$70.77	$74.58	+5.38%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---